The National Cancer Institute has awarded PGXL Technologies a contract worth $300,000 to develop a way to detect and separate circulating tumor cells not detected by existing technology. The initiative, which could aid in early cancer diagnosis, is one of four NCI-backed projects aimed at increasing the types of identifiable CTCs.

Related Summaries